We analysed the outcomes of 62 patients with refractory/relapsed diffuse large B-cell lymphoma (rrDLBCL) who had pre-transplantation fluorodeoxyglucose positron emission tomography/computed tomography (PET/CT) after R-DHAC (rituximab, dexamethasone, high-dose cytarabine, carboplatin) salvage chemotherapy, and were evaluated using Deauville criteria and total lesion glycolysis (TLG). A positive pretransplantation PET/CT with Deauville score of 5 was associated with shorter progression-free survival (PFS) (P = 0Á01), while a Deauville score of 4 was not predictive of outcome. Only pre-transplant TLG was significantly associated with both PFS (P = 0Á005) and overall survival (P = 0Á03). TLG deserves to be further investigated in prospective studies. , patients with rrDLBCL treated with R-DHAC salvage therapy and scheduled for HDT-ASCT after at least one course of chemotherapy at the Department of Haematology of the University Hospital of Bordeaux were retrospectively reviewed. Patients were eligible for ASCT if they exhibited chemosensitive disease after salvage chemotherapy. Patients with transformed B-cell non-Hodgkin lymphoma were excluded. Our Institutional Review Board (IRB) approved this retrospective study and waived the need for informed patient consent due to the retrospective nature of the work. The PET/CT data obtained at relapse and after salvage therapy were blindly and independently reviewed by two experienced nuclear medicine physicians using the Advantage Workstation (GE Healthcare, Milwaukee, WI, USA). The PET/CT results were classified using the Deauville 5-point scale: 1, no uptake; 2, uptake ≤ that of the mediastinal blood pool; 3, uptake > that of the pool but ≤ that of the liver; 4,

No abstract

No abstract